Product Images Aripiprazole

This text appears to be a chart showing the effect of certain drugs on a medication called Aripiprazole. The chart lists different classifications of drugs and specific examples of each that either inhibit or block certain enzymes. The chart also includes different pharmacokinetic (PK) measures such as AUC and Cmax. The last row of the chart lists Aripiprazole Fold Change and a percentage increase relative to the reference. However, without additional context, it is unclear what the reference is or what the increase in percentage means.*

This text provides information regarding the effect of different drugs on Aripiprazole, a medication used to treat mental/mood disorders. The table suggests that CYP3A4 inhibitors like ketoconazole and carbamazepine and a gastric acid blocker called famotidine may influence Aripiprazole's effectiveness. It also lists the fold change and 90% confidence interval of Dehydro-Aripiprazole when combined with different drugs, including quinidine, valproate, and lorazepam.*

This is a description of different factors affecting the pharmacokinetics of a drug called Avipiprazole in special populations. The text highlights the impact of genetic variations in CYP2D6 poor vs. extensive metabolizers on the AUC and Cmax of the drug, gender (female vs. male), age (18-64 vs. >65 years old) and the severity of hepatic and renal impairment on the drug's efficacy. There is also a graph showing the fold change of Avipiprazole and 90% confidence interval.*

This is a table displaying different variables related to drug metabolism and pharmacokinetics. It includes information such as the genetic profile of individuals (poor vs. extensive metabolizer), gender, age, hepatic and renal function, and different parameters related to drug concentration in the blood (Cmax, Uc,max, AUC). There is also a column showing the fold change and confidence interval of dehydro-aripiprazole, a metabolite of the drug aripiprazole.*

This appears to be a table or chart with headings and subheadings related to a study involving a drug called Aripiprazole and Placebo. The table contains numbers related to "Proportion with Relapse" and "Number of Subjects at Risk" over time, measured in days from Randomization. It is likely that this information is related to clinical trials or research studies involving the effectiveness of Aripiprazole compared to a Placebo.*

This is a graph comparing the relapse rate of patients taking aripiprazole versus those taking a placebo. The vertical axis shows the proportion of patients experiencing relapse, while the horizontal axis represents the number of days since randomization. The graph includes a table showing the number of subjects at risk at each time point.*

This is a graph showing the proportion of study participants experiencing relapse over time after receiving either Avipiprazole or a Placebo, with days from randomization on the X-axis and the proportion with relapse on the Y-axis. The text also includes the number of subjects at risk for each treatment group at each time point.*

Drug name: Aripiprazole Dosage: 2mg Form: Tablets Package size: 100 tablets Manufacturer: Cadla Healthcare L. Distributed by: Zyius Pharmaceuticals USA Prescription only. It contains 0.50mg of phenylalanine per tablet. Keep out of the reach of children. Store at controlled room temperature. For dosage and other information, refer to the package insert.*

This is a description of a medication named Aripiprazole in the form of tablets of 5mg each. The medication is only available through a prescription. The package contains 100 tablets and one of the ingredients contains 112mg. There are no other readable details about the usage or benefits of the medication. The manufacturer of this medication is Cadis Hestresr L. and it is distributed by Prmaceuticats USA Inc.*

This is a description of a medication, specifically Aripiprazole in the form of 15mg tablets. The NDC (National Drug Code) number associated with it is 68382-084-16. The medication is dispensed separately for each patient. The packaging contains 90 tablets. The medication is intended for use with adult patients. It is important to keep the medication out of reach of children. The medication is manufactured by Cadila Healthcare Ltd. and distributed by Zydus Pharmaceuticals USA Inc. The label contains dosage information and a warning for people with phenylketonuria.*

This is a medication called Aripiprazole provided in tablet form. The dosage is not clear from the available text. It contains 226 mg of a substance called Phenyletonurics which may be important for people with specific health concerns. The medication is manufactured by Cadla Hedreare L in India and distributed by Zyius Phamaceutials USA Inc. The text includes storage instructions to keep the tablets at a temperature no higher than 25°C or 68°F.*

This is a description of a medication called Aripiprazole. It comes in the form of tablets with a dosage of 30mg. The medication is dispensed in a container and should be taken according to specific guidelines. The packaging contains information about the manufacturer and the number of tablets included. There is a warning that the medication contains a specific amount of phenylalanine, which is a concern for individuals with Phenylketonuria.*